TABLE 2.
Adverse symptoms and treatment at home
| HM group (n = 17) | UM group (n = 16) | P‐value | |
|---|---|---|---|
| Number of intakes of OIT | 4916 | 4383 | |
| Number of adverse symptoms, n (%) | 396 (8.1%) | 419 (9.6%) | .01 |
| Severity of symptoms | |||
| Mild | 363 (7.4%) | 357 (8.1%) | .17 |
| Moderate | 32 (0.7%) | 62 (1.4%) | .0002 |
| Severe | 1 (0.02%) | 0 (0.0%) | ‐ |
| Organ system of symptoms | |||
| Skin | 134 (2.7%) | 127 (2.4%) | .61 |
| Mucosal | 285 (5.8%) | 215 (4.9%) | .06 |
| Respiratory | 59 (1.2%) | 105 (2.6%) | <.0001 |
| Gastrointestinal | 111 (2.3%) | 56 (1.3%) | .0003 |
| Cardiovascular | 0 (0.0%) | 1 (0.02%) | ‐ |
| Anaphylaxis | 1 (0.02%) | 2 (0.05%) | ‐ |
| Total number of symptoms requiring any treatments | 107 (2.2%) | 103 (2.3%) | .57 |
| Antihistamines | 86 (1.7%) | 90 (2.1%) | .28 |
| Corticosteroids | 7 (0.1%) | 28 (0.4%) | <.0001 |
| β2‐stimulant inhalation | 30 (0.6%) | 42 (1.0%) | .06 |
| Adrenaline | 1 (0.02%) | 1 (0.02%) | ‐ |
The patients' guardians kept a daily record of ingestion, symptoms, and treatment requirements. Patients visited the hospital at 1, 3, 6, 9, and 12 mo from the initiation of OIT. At the hospital visit, we checked the diary and recorded adverse symptoms. If moderate or severe symptoms developed, the patients' guardians reported these to the investigators via telephone.
Abbreviations: HM, heated milk; OIT, oral immunotherapy; UM, unheated milk.